Science 27 June 1986: Vol. 232. no. 4758, pp. 1644 - 1646 DOI: 10.1126/science.3012781

Prev | Table of Contents | Next

Articles

Clinical Relevance of HER2 Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer.

G. Curigliano, G. Viale, V. Bagnardi, L. Fumagalli, M. Locatelli, N. Rotmensz, R. Ghisini, M. Colleoni, E. Munzone, P. Veronesi, et al. (2009)
J. Clin. Oncol. 27, 5693-5699
 |  Abstract »  |  Full Text »  |  PDF »

Cell Lines as Candidate Reference Materials for Quality Control of ERBB2 Amplification and Expression Assays in Breast Cancer.

Y. Xiao, X. Gao, S. Maragh, W. G. Telford, and A. Tona (2009)
Clin. Chem. 55, 1307-1315
 |  Abstract »  |  Full Text »  |  PDF »

Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial.

M. Dowsett, M. Procter, W. McCaskill-Stevens, E. de Azambuja, U. Dafni, J. Rueschoff, B. Jordan, S. Dolci, M. Abramovitz, O. Stoss, et al. (2009)
J. Clin. Oncol. 27, 2962-2969
 |  Abstract »  |  Full Text »  |  PDF »

A Negative Feedback Regulatory Loop Associates the Tyrosine Kinase Receptor ERBB2 and the Transcription Factor GATA4 in Breast Cancer Cells.

G. Hua, B. Zhu, F. Rosa, N. Deblon, J. Adelaide, B. Kahn-Perles, D. Birnbaum, and J. Imbert (2009)
Mol. Cancer Res. 7, 402-414
 |  Abstract »  |  Full Text »  |  PDF »

Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers.

S. Chia, B. Norris, C. Speers, M. Cheang, B. Gilks, A. M. Gown, D. Huntsman, I. A. Olivotto, T. O. Nielsen, and K. Gelmon (2008)
J. Clin. Oncol. 26, 5697-5704
 |  Abstract »  |  Full Text »  |  PDF »

Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and Pathologists.

A. Carbone, G. Botti, A. Gloghini, G. Simone, M. Truini, M. P. Curcio, P. Gasparini, A. Mangia, T. Perin, S. Salvi, et al. (2008)
J. Mol. Diagn. 10, 527-536
 |  Abstract »  |  Full Text »  |  PDF »

Deconvolution-based Dynamic Contrast-enhanced MR Imaging of Breast Tumors: Correlation of Tumor Blood Flow with Human Epidermal Growth Factor Receptor 2 Status and Clinicopathologic Findings--Preliminary Results.

S. Makkat, R. Luypaert, T. Stadnik, C. Bourgain, S. Sourbron, M. Dujardin, J. De Greve, and J. De Mey (2008)
Radiology 249, 471-482
 |  Abstract »  |  Full Text »  |  PDF »

Trastuzumab-Induced Hepatotoxicity.

S. Srinivasan, V. Parsa, C. Y Liu, and J. A Fontana (2008)
Ann. Pharmacother. 42, 1497-1501
 |  Abstract »  |  Full Text »  |  PDF »

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.

C. Gravalos and A. Jimeno (2008)
Ann. Onc. 19, 1523-1529
 |  Abstract »  |  Full Text »  |  PDF »

Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression.

C. K. Anders, D. S. Hsu, G. Broadwater, C. R. Acharya, J. A. Foekens, Y. Zhang, Y. Wang, P. K. Marcom, J. R. Marks, P. G. Febbo, et al. (2008)
J. Clin. Oncol. 26, 3324-3330
 |  Abstract »  |  Full Text »  |  PDF »

Overexpression of ERBB-2 was more frequently detected in malignant than benign pheochromocytomas by multiplex ligation-dependent probe amplification and immunohistochemistry.

W. Yuan, W. Wang, B. Cui, T. Su, Y. Ge, L. Jiang, W. Zhou, and G. Ning (2008)
Endocr. Relat. Cancer 15, 343-350
 |  Abstract »  |  Full Text »  |  PDF »

Targeting IFN-{alpha} to B Cell Lymphoma by a Tumor-Specific Antibody Elicits Potent Antitumor Activities.

T.-H. Huang, K. R. Chintalacharuvu, and S. L. Morrison (2007)
J. Immunol. 179, 6881-6888
 |  Abstract »  |  Full Text »  |  PDF »

Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node-positive patients.

H. Kim, T. Yoo, D. Park, J. Park, Y. Cho, C. Sohn, W. Jeon, B. Kim, M. Kim, S. Chae, et al. (2007)
Ann. Onc. 18, 892-897
 |  Abstract »  |  Full Text »  |  PDF »

Brain Metastases: The HER2 Paradigm.

N. U. Lin and E. P. Winer (2007)
Clin. Cancer Res. 13, 1648-1655
 |  Abstract »  |  Full Text »  |  PDF »

Effect of ATM, CHEK2 and ERBB2 TAGSNPs and haplotypes on endometrial cancer risk.

K. Einarsdottir, K. Humphreys, C. Bonnard, Y. Li, Y. Li, K. S. Chia, E. T. Liu, P. Hall, J. Liu, and S. Wedren (2007)
Hum. Mol. Genet. 16, 154-164
 |  Abstract »  |  Full Text »  |  PDF »

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.

A. C. Wolff, M. E. H. Hammond, J. N. Schwartz, K. L. Hagerty, D. C. Allred, R. J. Cote, M. Dowsett, P. L. Fitzgibbons, W. M. Hanna, A. Langer, et al. (2007)
J. Clin. Oncol. 25, 118-145
 |  Abstract »  |  Full Text »  |  PDF »

Antitumor Effect of Trastuzumab for Pancreatic Cancer with High HER-2 Expression and Enhancement of Effect by Combined Therapy with Gemcitabine..

K. Kimura, T. Sawada, M. Komatsu, M. Inoue, K. Muguruma, T. Nishihara, Y. Yamashita, N. Yamada, M. Ohira, and K. Hirakawa (2006)
Clin. Cancer Res. 12, 4925-4932
 |  Abstract »  |  Full Text »  |  PDF »

Vaccination with Human HER-2/neu (435-443) CTL Peptide Induces Effective Antitumor Immunity against HER-2/neu-Expressing Tumor Cells In vivo..

A. D. Gritzapis, L. G. Mahaira, S. A. Perez, N. T. Cacoullos, M. Papamichail, and C. N. Baxevanis (2006)
Cancer Res. 66, 5452-5460
 |  Abstract »  |  Full Text »  |  PDF »

A Trimeric Anti-HER2/neu ScFv and Tumor Necrosis Factor-{alpha} Fusion Protein Induces HER2/neu Signaling and Facilitates Repair of Injured Epithelia.

T.-H. Huang and S. L. Morrison (2006)
J. Pharmacol. Exp. Ther. 316, 983-991
 |  Abstract »  |  Full Text »  |  PDF »

Expression of HER2 and the Coamplified Genes GRB7 and MLN64 in Human Breast Cancer: Quantitative Real-time Reverse Transcription-PCR as a Diagnostic Alternative to Immunohistochemistry and Fluorescence In situ Hybridization.

U. Vinatzer, B. Dampier, B. Streubel, M. Pacher, M. J. Seewald, C. Stratowa, K. Kaserer, and M. Schreiber (2005)
Clin. Cancer Res. 11, 8348-8357
 |  Abstract »  |  Full Text »  |  PDF »

Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer.

H. J. Huang, P. Neven, M. Drijkoningen, R. Paridaens, H. Wildiers, E. Van Limbergen, P. Berteloot, F. Amant, I. Vergote, and M. R. Christiaens (2005)
Ann. Onc. 16, 1755-1761
 |  Abstract »  |  Full Text »  |  PDF »

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer..

M. J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, et al. (2005)
N. Engl. J. Med. 353, 1659-1672
 |  Abstract »  |  Full Text »  |  PDF »

Role of Chromogenic in Situ Hybridization (CISHTM) in the Evaluation of HER2 Status in Breast Carcinoma: Comparison with Immunohistochemistry and Fish.

E. Li-Ning-T, R. Ronchetti, C. Torres-Cabala, and M. J. Merino (2005)
International Journal of Surgical Pathology 13, 343-351
 |  Abstract »  |  PDF »

Reorganization of ErbB Family and Cell Survival Signaling after Knock-down of ErbB2 in Colon Cancer Cells.

Y. P. Hu, S. Venkateswarlu, N. Sergina, G. Howell, P. St. Clair, L. E. Humphrey, W. Li, J. Hauser, E. Zborowska, J. K. V. Willson, et al. (2005)
J. Biol. Chem. 280, 27383-27392
 |  Abstract »  |  Full Text »  |  PDF »

A Haplotype Analysis of HER-2 Gene Polymorphisms: Association with Breast Cancer Risk, HER-2 Protein Expression in the Tumor, and Disease Recurrence in Korea.

W. Han, D. Kang, J. E. Lee, I. A. Park, J.-Y. Choi, K.-M. Lee, J. Y. Bae, S. Kim, E.-S. Shin, J. E. Lee, et al. (2005)
Clin. Cancer Res. 11, 4775-4778
 |  Abstract »  |  Full Text »  |  PDF »

Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.

H J Huang, P Neven, M Drijkoningen, R Paridaens, H Wildiers, E Van Limbergen, P Berteloot, F Amant, I Vergote, and M R Christiaens (2005)
J. Clin. Pathol. 58, 611-616
 |  Abstract »  |  Full Text »  |  PDF »

A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis.

J. Norum, T. Risberg, and J. A. Olsen (2005)
Ann. Onc. 16, 909-914
 |  Abstract »  |  Full Text »  |  PDF »

HER2 Overexpression Increases Sensitivity to Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, through Inhibition of HER2/HER3 Heterodimer Formation in Lung Cancer Cells.

A. Hirata, F. Hosoi, M. Miyagawa, S.-i. Ueda, S. Naito, T. Fujii, M. Kuwano, and M. Ono (2005)
Cancer Res. 65, 4253-4260
 |  Abstract »  |  Full Text »  |  PDF »

The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk.

B. Frank, K. Hemminki, M. Wirtenberger, J. L. Bermejo, P. Bugert, R. Klaes, R. K. Schmutzler, B. Wappenschmidt, C. R. Bartram, and B. Burwinkel (2005)
Carcinogenesis 26, 643-647
 |  Abstract »  |  Full Text »  |  PDF »

Low-Dose Dietary Phytoestrogen Abrogates Tamoxifen-Associated Mammary Tumor Prevention.

B. Liu, S. Edgerton, X. Yang, A. Kim, D. Ordonez-Ercan, T. Mason, K. Alvarez, C. McKimmey, N. Liu, and A. Thor (2005)
Cancer Res. 65, 879-886
 |  Abstract »  |  Full Text »  |  PDF »

Her-2/neu Overexpression and Amplification in Uterine Papillary Serous Carcinoma.

B. M. Slomovitz, R. R. Broaddus, T. W. Burke, N. Sneige, P. T. Soliman, W. Wu, C. C. Sun, M. F. Munsell, D. M. Gershenson, and K. H. Lu (2004)
J. Clin. Oncol. 22, 3126-3132
 |  Abstract »  |  Full Text »  |  PDF »

Combining trastuzumab (Herceptin(R)) with hormonal therapy in breast cancer: what can be expected and why?.

A. Jones (2003)
Ann. Onc. 14, 1697-1704
 |  Abstract »  |  Full Text »  |  PDF »

Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells.

F. Leone, E. Perissinotto, G. Cavalloni, V. Fonsato, S. Bruno, N. Surrenti, D. Hong, A. Capaldi, M. Geuna, W. Piacibello, et al. (2003)
J. Leukoc. Biol. 74, 593-601
 |  Abstract »  |  Full Text »  |  PDF »

Trastuzumab and Interleukin-2 in HER2-positive Metastatic Breast Cancer: A Pilot Study.

T. Repka, E. G. Chiorean, J. Gay, K. E. Herwig, V. K. Kohl, D. Yee, and J. S. Miller (2003)
Clin. Cancer Res. 9, 2440-2446
 |  Abstract »  |  Full Text »  |  PDF »

Prognostic Significance of p53, nm23, PCNA and c-erbB-2 in Gastric Cancer.

K. E. Lee, H.-J. Lee, Y. H. Kim, H. J. Yu, H.-K. Yang, W.-H. Kim, K. U. Lee, K. J. Choe, and J.-P. Kim (2003)
Jpn. J. Clin. Oncol. 33, 173-179
 |  Abstract »  |  Full Text »  |  PDF »

ErbB-2 Activates Stat3alpha in a Src- and JAK2-dependent Manner.

Z. Ren and T. S. Schaefer (2002)
J. Biol. Chem. 277, 38486-38493
 |  Abstract »  |  Full Text »  |  PDF »

c-erb B-2 Expression Is Associated with Tumor Location and Venous Invasion and Influences Survival of Patients with Gastric Carcinoma.

J. Pinto-de-Sousa, L. David, R. Almeida, D. Leitao, J. R. Preto, M. Seixas, and A. Pimenta (2002)
International Journal of Surgical Pathology 10, 247-256
 |  Abstract »  |  PDF »

A Testing Algorithm for Determination of HER2 Status in Patients with Breast Cancer.

D. W. Nichols, D. J. Wolff, S. Self, J. S. Metcalf, D. Jacobs, R. Kneuper-Hall, and J. C. Cate IV (2002)
Ann. Clin. Lab. Sci. 32, 3-11
 |  Abstract »  |  Full Text »  |  PDF »

HER-2/neu-Positive Breast Carcinoma: Molecular Concomitants by Proteomic Analysis and their Therapeutic Implications.

R. E. Brown (2002)
Ann. Clin. Lab. Sci. 32, 12-21
 |  Abstract »  |  Full Text »  |  PDF »

Expression and Gene Copy Number Analysis of ERBB2 Oncogene in Prostate Cancer.

K. J. Savinainen, O. R. Saramaki, M. J. Linja, O. Bratt, T. L. J. Tammela, J. J. Isola, and T. Visakorpi (2002)
Am. J. Pathol. 160, 339-345
 |  Abstract »  |  Full Text »  |  PDF »

A Case with HER2-overexpressing Breast Cancer Completely Responded to Humanized anti-HER2 Monoclonal Antibody.

M. Ohta, Y. Tokuda, Y. Suzuki, M. Kubota, T. Watanabe, H. Fujii, Y. Sasaki, T. Niwa, H. Makuuchi, and T. Tajima (2001)
Jpn. J. Clin. Oncol. 31, 553-556
 |  Abstract »  |  Full Text »  |  PDF »

Gelsolin as a Negative Prognostic Factor and Effector of Motility in erbB-2-positive Epidermal Growth Factor Receptor-positive Breast Cancers.

A. D. Thor, S. M. Edgerton, S. Liu, D. H. Moore II, and D. J. Kwiatkowski (2001)
Clin. Cancer Res. 7, 2415-2424
 |  Abstract »  |  Full Text »  |  PDF »

Novel Compounds in the Therapy of Breast Cancer: Opportunities for Integration with Docetaxel.

A. W. Tolcher (2001)
Oncologist 6, 40-44
 |  Abstract »  |  Full Text »  |  PDF »

Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification.

A. D. Seidman, M. N. Fornier, F. J. Esteva, L. Tan, S. Kaptain, A. Bach, K. S. Panageas, C. Arroyo, V. Valero, V. Currie, et al. (2001)
J. Clin. Oncol. 19, 2587-2595
 |  Abstract »  |  Full Text »  |  PDF »

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2.

D. J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, et al. (2001)
N. Engl. J. Med. 344, 783-792
 |  Abstract »  |  Full Text »  |  PDF »

Recombinant Anti-Human HER2/neu IgG3-(GM-CSF) Fusion Protein Retains Antigen Specificity and Cytokine Function and Demonstrates Antitumor Activity.

J. S. Dela Cruz, K. R. Trinh, S. L. Morrison, and M. L. Penichet (2000)
J. Immunol. 165, 5112-5121
 |  Abstract »  |  Full Text »  |  PDF »

Impact of genomics on drug discovery and clinical medicine.

G. Emilien, M. Ponchon, C. Caldas, O. Isacson, and J.-M. Maloteaux (2000)
QJM 93, 391-423
 |  Abstract »  |  Full Text »  |  PDF »

c-erbB-2 Is of Independent Prognostic Relevance in Gastric Cancer and Is Associated With the Expression of Tumor-Associated Protease Systems.

H. Allgayer, R. Babic, K. U. Gruetzner, A. Tarabichi, F. W. Schildberg, and M. M. Heiss (2000)
J. Clin. Oncol. 18, 2201-2209
 |  Abstract »  |  Full Text »  |  PDF »

Population-Based, Case-Control Study of HER2 Genetic Polymorphism and Breast Cancer Risk.

D. Xie, X.-O. Shu, Z. Deng, W.-Q. Wen, K. E. Creek, Q. Dai, Y.-T. Gao, F. Jin, and W. Zheng (2000)
J Natl Cancer Inst 92, 412-417
 |  Abstract »  |  Full Text »  |  PDF »

Combination of EGFR, HER-2/neu, and HER-3 Is a Stronger Predictor for the Outcome of Oral Squamous Cell Carcinoma Than Any Individual Family Members.

W. Xia, Y.-K. Lau, H.-Z. Zhang, F.-Y. Xiao, D. A. Johnston, A.-R. Liu, L. Li, R. L. Katz, and M.-C. Hung (1999)
Clin. Cancer Res. 5, 4164-4174
 |  Abstract »  |  Full Text »  |  PDF »

SEQUENCE-DEPENDENT ENHANCEMENT OF PACLITAXEL TOXICITY IN NON-SMALL CELL LUNG CANCER BY 17-ALLYLAMINO 17-DEMETHOXYGELDANAMYCIN.

D. M. Nguyen, A. Chen, A. Mixon, D. S. Schrump, and S. J. A. Roth (1999)
J. Thorac. Cardiovasc. Surg. 118, 908-915
 |  Abstract »  |  Full Text »  |  PDF »

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease.

M. A. Cobleigh, C. L. Vogel, D. Tripathy, N. J. Robert, S. Scholl, L. Fehrenbacher, J. M. Wolter, V. Paton, S. Shak, G. Lieberman, et al. (1999)
J. Clin. Oncol. 17, 2639
 |  Abstract »  |  Full Text »  |  PDF »

Relationship between Protease Activity and neu Oncogene Expression in Patients with Oral Leukoplakia Treated with the Bowman Birk Inhibitor.

X. S. Wan, F. L. Meyskens Jr., W. B. Armstrong, T. H. Taylor, and A. R. Kennedy (1999)
Cancer Epidemiol. Biomarkers Prev. 8, 601-608
 |  Abstract »  |  Full Text »

A New cis Element Is Involved in the HER2 Gene Overexpression in Human Breast Cancer Cells.

M. Grooteclaes, D. Vernimmen, S. Plaza, F. Pasleau, D. Hodzic, and R. Winkler-Gol (1999)
Cancer Res. 59, 2527-2531
 |  Abstract »  |  Full Text »  |  PDF »

Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung.

C.-C. Hsieh, K.-C. Chow, H.-J. Fahn, C.-M. Tsai, W.-Y. Li, M.-H. Huang, and L.-S. Wang (1998)
Ann. Thorac. Surg. 66, 1159-1163
 |  Abstract »  |  Full Text »  |  PDF »

Activation of Neu (ErbB-2) Mediated by Disulfide Bond-Induced Dimerization Reveals a Receptor Tyrosine Kinase Dimer Interface.

C. L. Burke and D. F. Stern (1998)
Mol. Cell. Biol. 18, 5371-5379
 |  Abstract »  |  Full Text »

Effect of Dimerization on Signal Transduction and Biological Function of Oncogenic Ros, Insulin, and Insulin-like Growth Factor I Receptors.

J. L.-K. Chan, M. Lai, and L.-H. Wang (1997)
J. Biol. Chem. 272, 146-153
 |  Abstract »  |  Full Text »  |  PDF »

c-erbB-2/p185-Directed Therapy in Human Lung Adenocarcinoma.

J. M. Snider, L. J. Bushnell, L. C. Chen, and L. A. Lanza (1996)
Ann. Thorac. Surg. 62, 1454-1459
 |  Abstract »  |  Full Text »

c-erbB-2 Oncoprotein Immunoreactivity in Gallbladder and Biliary Tract Cancers.

C. S. Lee and A. Pirdas (1996)
International Journal of Surgical Pathology 4, 71-76
 |  Abstract »  |  PDF »

Isolation of a novel receptor cDNA establishes the existence of two PDGF receptor genes.

T Matsui, M Heidaran, T Miki, N Popescu, W La Rochelle, M Kraus, J Pierce, and S Aaronson (1989)
Science 243, 800-804
 |  Abstract »  |  PDF »

The c-erbB-2 Gene Encodes a Receptor-like Protein with Tyrosine Kinase Activity.

K. Toyoshima, K. Semba, T. Akiyama, S. Ikawa, and T. Yamamoto (1986)
Cold Spring Harb Symp Quant Biol 51, 977-982
 |  Abstract »  |  PDF »

c-Cbl Is a Suppressor of the Neu Oncogene.

G. Levkowitz, S. Oved, L. N. Klapper, D. Harari, S. Lavi, M. Sela, and Y. Yarden (2000)
J. Biol. Chem. 275, 35532-35539
 |  Abstract »  |  Full Text »  |  PDF »

To Advertise   |   Find Products